Beckley Oncology Associates v. Rami Abumasmah

993 F.3d 261
Court of Appeals for the Fourth Circuit·Decided April 8, 2021·No. 19-1751·Published·Cited by 2 cases

Opinion

PUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 19-1751

BECKLEY ONCOLOGY ASSOCIATES, INC., Plaintiff − Appellant,

v.

RAMI ABUMASMAH, M.D., Defendant – Appellee.

Appeal from the United States District Court for the Southern District of West Virginia, at Beckley. Irene C. Berger, District Judge. (5:18−cv−01549)

Argued: December 11, 2020 Decided: April 8, 2021

Before GREGORY, Chief Judge, and KING and DIAZ, Circuit Judges.

Appeal dismissed by published opinion. Judge Diaz wrote the opinion, in which Chief Judge Gregory and Judge King joined.

ARGUED: Justin M. Harrison, JACKSON KELLY, PLLC, Charleston, West Virginia, for Appellant. Omar Dirar Ahmad, EVES LAW FIRM, PLLC, Huntington, West Virginia, for Appellee. ON BRIEF: Grace E. Hurney, JACKSON KELLY, PLLC, Charleston, West Virginia, for Appellant.

DIAZ, Circuit Judge:

Beckley Oncology Associates (“BOA”) appeals from the district court’s dismissal of its complaint seeking to vacate an arbitration award in favor of Dr. Rami Abumasmah, an oncologist and former BOA employee. The arbitrator awarded relief to Dr. Abumasmah in a compensation dispute following BOA’s termination of his employment. The employment agreement between BOA and Abumasmah purported to waive both judicial and appellate review of the arbitrator’s decision. Because the waiver of appellate review is enforceable, we dismiss BOA’s appeal.

I.

A.

BOA provides cancer treatment from its office in Beckley, West Virginia. Early in 2012, BOA recruited Dr. Abumasmah to join the practice as a medical oncologist. After several months of negotiations, Abumasmah signed an employment agreement with BOA. Among other things, the agreement provided that the parties would arbitrate

All disputes, controversies and disagreements between the Employer and Physician connected with, related to or arising out of (i) the employment relationship between the parties, including its commencement and termination and all activities throughout; (ii) the execution, delivery, interpretation or enforcement of this Employment Agreement; (iii)[ ]any other written or oral agreements between the parties, and (iv) any business or professional activities between the parties or any other rights, duties, or responsibilities between the parties arising out of their business or professional affairs[.]

J.A. 30–31. The parties further agreed that the arbitrator’s decision “shall be final and conclusive and enforceable in any court of competent jurisdiction without any right of judicial review or appeal.” J.A. 31 (emphasis added).

The two-year employment agreement (which BOA drafted) would automatically renew for successive one-year terms, unless either party gave 90-days’ notice of termination, which could be without cause. Abumasmah would be eligible to join the partnership at the end of the initial two-year employment term, if the current shareholders approved.

The agreement included the following incentive bonus provision:

Employer may, in its sole and absolute discretion, declare and pay bonuses to Physician from time to time. This, notwithstanding, Employer agrees to pay Physician an incentive bonus during the initial two year term of this agreement as follows: In addition to a base salary of $275,000.00 per year, the physician shall be entitled to incentive bonus compensation based on gross collections (receipts) as follows in each year of the initial term of this agreement: . . . The incentive bonus payment shall be made to Physician following the completion of the first 12 months of this agreement, and subsequently following the completion of the second 12 months of the initial term. The specific terms of this incentive bonus are provided only for the initial term of this agreement, and are subject to renegotiation in subsequent renewals of this agreement.

J.A. 24.

Finally, the agreement provided that “[t]he invalidity or unenforceability of any provision in the Agreement shall not in any way affect the validity or enforceability of any other provision[,] and this Agreement shall be construed in all respects as if such invalid or unenforceable provision had never been in the Agreement.” J.A. 31–32.

B.

Dr. Abumasmah began working at BOA in July of 2012. During his first six months at BOA, Abumasmah explored the possibility of joining the partnership but was uncertain whether he could afford the requisite capital contribution. In 2014, Abumasmah was invited to join the partnership, but he declined.

Early the following year, Abumasmah told BOA that he planned to leave the country for at least six months so that he could travel to Amman, Jordan to care for his mother. Abumasmah’s last day at BOA was June 25, 2015. He arrived in Jordan shortly thereafter, where he has remained. Before he left, Abumasmah told BOA that he didn’t expect to receive compensation during his indefinite leave and offered to resign.

BOA terminated Abumasmah’s employment on his last day and sent him a separation agreement. Abumasmah disagreed with several of the agreement’s terms. Relevant here is the provision stating that the incentive bonus payment of $72,994, which he received in June of 2015, was the entire bonus due for 2014–2015.

Abumasmah received annual incentive bonuses of $141,000 and $242,000 in 2012– 13 and 2013–14 respectively. He didn’t receive an accounting of his gross collections for 2014–15, whereas he received such reports for his first two years of employment. According to BOA, Abumasmah did not receive a report for 2014–15, because he wasn’t entitled to an incentive bonus for that year. 1

1 It’s unclear then why BOA paid Abumasmah any incentive bonus for 2014–15.

Abumasmah generated more revenue during each successive year of his employment, bringing in $7.1 million in 2014–15. Based on the formula for calculating his incentive bonus in effect for the first two years of his employment, Abumasmah claimed that he should have received a $328,070.57 bonus for his 2014–15 collections.

Abumasmah sought arbitration of his claims against BOA. The arbitrator determined that Abumasmah was entitled to an incentive bonus for his third year of employment, though not on the same terms as before. Instead, the arbitrator concluded that Abumasmah’s incentive bonus “shall be determined by the incentive bonus methodology utilized by [BOA] for its employee physicians.” J.A. 48. If BOA had no such methodology, or if the result would be “unjust in these circumstances,” then the bonus would be determined based on the methods “commonly found” for calculating incentive bonuses for physicians. Id. The arbitrator noted that section 16 of the employment agreement gave him “the right and duty to give appropriate equitable and legal relief.” Id. And, said the arbitrator, the parties agreed that West Virginia law—which recognizes the concept of unjust enrichment—governed the terms of the Employment Agreement. Id.

After additional briefing from the parties on the method for calculating the incentive bonus, the arbitrator awarded Abumasmah $167,030, 2 2.5% of the gross revenue he generated. The arbitrator awarded this amount “[t]o prevent the unjust enrichment of

2 This amount appears to include the $72,994 incentive bonus BOA paid Dr.

Abumasmah for 2015, as the arbitrator stated that Abumasmah’s total compensation for 2014–15 would be “$442,030 ($275,000 in base salary plus the $167,030 incentive bonus).” J.A. 19.

[BOA] and to compensate [Dr. Abumasmah] for the extraordinary revenue which he generated during his third year of employment.” J.A. 18.

Free access — add to your briefcase to read the full text and ask questions with AI

Beckley Oncology Associates v. Rami Abumasmah, 993 F.3d 261 (4th Cir. 2021).

993 F.3d 261 (Beckley Oncology Associates v. Rami Abumasmah) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related